Timothy RoeCEO/Principalexpand_lessTimothy Roe is a Life Sciences executive with a uniquely diverse background. He began his career as a Drug Rep and advanced through a vast number of functional areas across large and small biopharma organizations. An analytical leader, collaborator and C-suite/board advisor with experience managing global corporate initiatives resulting in material improvements to the bottom line and shareholder value.
Timothy has worked across many therapeutic areas including ultra-rare diseases, oncology, neuroscience, infectious diseases, women’s health, nephrology, urology, allergy/asthma and cardiovascular.
Timothy’s entrepreneurial leadership style, collaborative approach, and expertise in corporate program management and organizational transformations is highly-regarded across the industry. His breadth of scope covers emerging and established bio-pharmaceuticals organizations. Timothy has provided consulting and advisement services to Wall Street analysts and to top US and international management consulting firms.
Timothy is a former member of the board of directors at IronNimbus, Inc., a US-based medical information long-term storage and business continuity platform built in a former underground nuclear bunker outside of Houston, TX.
Timothy's career began in the Financial Sector before moving into Life Sciences. He began his pharmaceutical career as a sales rep and progressed to district and regional sales management. Timothy was the #1 rep in the country for G.D. Searle two years in a row, including the #1 Rookie rep. GD Searle’s parent organization, Monsanto, selected Timothy to participate in their highly ambitious management rotation program.
Timothy's client-side experience includes senior Commercial and Medical Affairs roles with the “Big-C” brands; the launch of Celebrex (now Pfizer), Cipro (Bayer) and Claritin/Clarinex (Schering-Plough/Merck). He has also managed various size brands in smaller organizations including those in niche and specialty markets.
Timothy attended the LC Smith College of Engineering and the College of Arts & Sciences at Syracuse University. He did his graduate work at the Rochester Institute of Technology and the University of Hartford where he earned a dual MBA in Marketing and Finance with “distinction” honors. Timothy attended Northwestern University’s Kellogg School where he studied Marketing and Business Transformations. He earned a Drug Safety Regulation Certification from the UK Royal College of Physicians.
When you engage M2D Global Life Sciences, you have access to amazing expertise with over a century of combined experience in every facet of the business. This enables us to deliver programs of the highest operational quality, efficiency and effectiveness.
John Price, MB ChB PhDMB ChB PhDexpand_less
John Price is a physician executive with experience at US based global pharmaceutical companies including big Pharma, consumer health and rare diseases, and a European Regulatory Agency. He has 27 years experience in drug development, Pharmacovigilance, Risk Management And Regulatory Affairs.
John is a solution-oriented visionary architect and leader of global Pharmacovigilance and Regulatory Operations departments supporting the drug lifecycle across all therapeutic areas. He is passionate about driving effectiveness and efficiencies to avoid excessive spend simply complying with regulatory requirements and save valuable dollars for the development of future medicines, and helping companies that possess limited resource and specialist expertise to market their products.
Pam YourishType a description for the list item hereexpand_less
Pam Yourish is an innovative business transformation and change leader. She helps clients plan and execute complex business transitions, from process improvements to post-merger integrations. Pam’s work focuses on helping companies operationalize strategic change and ensure that objectives are not just met but embedded in the fabric of the organization. Pam is also a certified leadership coach who partners with executives and teams to navigate challenging transitions.
Many years of hands-on experience as practitioner blending the disciplines of project management and organizational change management, have led Pam to develop a strong integrated approach. She tailors this to the DNA of the client to drive lasting value. As a management consultant to biopharmaceutical companies, she brings a unique blend of expertise from both the clinical and commercial side of the business.
She has implemented lean supply chain and manufacturing capabilities, launched new organizational structures and workflows, designed innovative vendor management and CRO business partnering approaches, created and rolled out new aggregate reporting processes, managed post-acquisition functional integrations, built new operating models and led multiple pharmacovigilance drug safety process redesign efforts to improve compliance, quality and inspection readiness.
Pam founded Alchemy Advisors in 2004. Prior to that she worked for premier consulting firms including E&Y and PwC. Pam holds and an MBA from Columbia Business School, a Masters in Engineering from The Pennsylvania State University and a BS from Tufts University. Pam is a certified PMP®, Prince2® Project Management Professional, Prosci Certified Change Professional and a Lean Six Sigma Master Black Belt.
Jayne Douglas, MDType a description for the list item hereexpand_less
Jayne Douglas is a top-performing, growth-oriented healthcare and life sciences professional offering extensive experience driving strategy, operational efficiencies and results for corporations in the medical device, pharma, biotech and healthcare industries.
Jayne is consistently successful in leading and aligning programs, departments and colleagues through change. She is recognized as best-in-class resource on leadership development and executive coaching. She is a skilled negotiator and strategic planner who is able to quickly assess situations to identify solutions and establish strategic relationships with management, physicians, and boards resulting in positive, healthy and innovative partnerships.
Uche Iloeje, MDType a description for the list item hereexpand_less
Uche Iloeje is an experienced biopharmaceutical executive with 17 years of accomplishments in heath economics, outcomes research, clinical research and medical affairs; starting his career in a large sized company but more recently, passionately focusing on small size innovative companies.
Uche is a medical doctor, and graduate of the College of Medicine, University of Nigeria, graduating in 1987. He is an internist (University of Connecticut, 1995) and a critical care medicine specialist (University of Pittsburgh 1996). He also completed a subspecialty training in occupational health whilst obtaining a master’s degree in chronic disease epidemiology (MPH, Yale University, 2001).
Uche started his career in the pharmaceutical industry in 2001 and his career has seen him working across multiple disease areas including HIV, Hepatitis B, anti-microbials, type II diabetes, stroke prevention in atrial fibrillation, non-alcoholic fatty liver disease, as well as such rare diseases as atypical hemolytic uraemic syndrome (aHUS), paroxysmal nocturnal haemoglobinuria (PNH), lysosomal acid lipase deficiency (LAL-D), hypophosphatasia (HPP), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).
Uche has been lead author or co-author in over 60 peer reviewed scientific publications, and has been published in such esteemed journals as JAMA, Gastroenterology, American Journal of Gastroenterology, Hepatology, American Journal of Cardiology, European Heart Journal, Diabetes Obesity and Metabolism, Pharmacoeconomics, HIV Medicine, Clinics in Liver Diseases, Clinical Infectious Diseases, Journal of Clinical Oncology, Journal of the National Cancer Institute, and American Journal of Epidemiology, to name a few. He was the originator of the very widely cited Risk Evaluation of Viral Elevation and Associated Liver diseases-HBV study (REVEAL-HBV study) which helped establish oral antiviral agents as the primary approach to treating chronic hepatitis B virus infection. This study supported a change in regulatory approvals of new therapies for this disease by establishing HBV-DNA levels as a validated surrogate marker, obviating the need for liver histopathology as the primary registration end point.
Uche is currently focused in developing medical affairs functions in the US for small size innovative biotechnology companies and is a member of several professional societies including the Medical Affairs Professional Society (MAPS) as well as the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).